This application for renewal of the University of Virginia Cancer Center requests support for leadership, administration, planning, shared resources, and developmental activities. Ours is a matrix cancer center that brings together 196 members from 30 Departments in the School of Medicine, School of Nursing and the Colleges of Arts and Sciences, and of Engineering, all of which reside on a single campus. The Cancer Center has seven research Programs: ? Six basic/translational Programs representing key scientific foci important for understanding cancer. 1-Cell Signaling; 2-Endocrinology;3-lmmunology;4-Migration and Metastasis;5-Structural Biology;6-Molecular Genetics. ? One translational/clinical Program, 7-Developmental Therapeutics, which has two sub-Programs: Immune Therapies;and Targeted Therapies, Biomarkers, and Imaging. This Program has as its principal mission the development and implementation of clinical research that draws on the basic science expertise of the Center. There are 8 members who are not aligned. The Cancer Center supports 14 Shared Resources: Advanced Microscopy, DMA Sciences, Flow Cytometry, Lymphocyte Culture, Mass Spectrometry, Protein Sciences, Small Animal Multimodality Imaging, Tissue Culture, Gene Targeting &Transgenic, Research Histology, Molecular Assessment &Preclinical Studies, Tissue Procurement, Biostatistics, and the Clinical Trials Office. During the past grant period the CCSG assisted in the recruitment of 33 new faculty to the University, and increased its membership by 26. Notable is the formation of a new Program, Molecular Genetics, comprised both of new recruits and previous members. NCI funding for the CCSG has increased from $6,648,872 (annual, direct) to $14,413,544, and total peer-reviewed funding from $32,814,939 to $68,130,838. This period has seen enhancement of the already outstanding basic science, increased cancer focus in every Program, and substantially increased clinical research activity. Clinical facilities have been renovated and expanded and ground has been broken on a new research building which will house our Immunotherapy program and our developing Women's Oncology program. A new clinical building is being planned. Major goals for the next grant period are to expand substantially the clinical research activities that draw on our basic science, further elevate the excellence and cancer focus of the basic sciences, and strengthen the foundation for achieving Comprehensive status at the next renewal.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-20
Application #
7771676
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-16
Project End
2012-01-31
Budget Start
2010-02-01
Budget End
2012-01-31
Support Year
20
Fiscal Year
2010
Total Cost
$2,410,577
Indirect Cost
Name
University of Virginia
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Melssen, Marit; Slingluff Jr, Craig L (2017) Vaccines targeting helper T cells for cancer immunotherapy. Curr Opin Immunol 47:85-92
Bullock, Timothy Nj (2017) TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines. Curr Opin Immunol 47:70-77
Scalici, Jennifer M; Arapovic, Sanja; Saks, Erin J et al. (2017) Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC). Cancer 123:977-984
Shukla, Girja S; Olson, Walter C; Pero, Stephanie C et al. (2017) Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies. J Transl Med 15:180
Keim-Malpass, Jessica; Mitchell, Emma M; DeGuzman, Pamela B et al. (2017) Legislative activity related to the human papillomavirus (HPV) vaccine in the United States (2006-2015): a need for evidence-based policy. Risk Manag Healthc Policy 10:29-32
Mills, Anne M; Paquette, Cherie; Terzic, Tatjana et al. (2017) CK7 Immunohistochemistry as a Predictor of CIN1 Progression: A Retrospective Study of Patients From the Quadrivalent HPV Vaccine Trials. Am J Surg Pathol 41:143-152
Rohani, Ali; Moore, John H; Kashatus, Jennifer A et al. (2017) Label-Free Quantification of Intracellular Mitochondrial Dynamics Using Dielectrophoresis. Anal Chem 89:5757-5764
Wages, N A; Slingluff Jr, C L; Petroni, G R (2017) Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies. Ann Oncol 28:696-701
O'Brien, Carleigh A; Overall, Christopher; Konradt, Christoph et al. (2017) CD11c-Expressing Cells Affect Regulatory T Cell Behavior in the Meninges during Central Nervous System Infection. J Immunol 198:4054-4061
Bullock, Timothy Nj (2017) Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer. Curr Opin Immunol 45:82-88

Showing the most recent 10 out of 472 publications